RxDoctor Payments Data

Qing Ren, MD

Nephrology · San Marcos, TXNPI 1316137722

Payments from drug & device makers

$1,705in general payments, 2019–2025

Across 84 payments — averaging $20.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$356
  • Novartis$208
  • Vifor Pharma, Inc.$174
  • Fresenius USA Marketing, Inc.$172
  • Bayer$169
  • ANI Pharmaceuticals, Inc.$104
  • plus $522 from 13 others

What the payments were for

  • Food & beverage$1,69099%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,705 in reported general payments places this provider in the 50th percentile of 1,070 nephrology providers in Texas.

See all nephrology providers in Texas

Medicare billing

Part B allowed, 2024
$199,601
Medicare patients
261
Services billed
1,462

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide70$214,244
XphozahTenapanor Hcl58$182,032
FarxigaDapagliflozin Propanediol172$136,158
KerendiaFinerenone136$114,527
VeltassaPatiromer Calcium Sorbitex70$70,044
AuryxiaFerric Citrate34$65,596
LokelmaSodium Zirconium Cyclosilicate36$26,771
Lanthanum Carbonate32$23,996
JardianceEmpagliflozin37$21,439
Sevelamer Carbonate77$16,106
ClinisolParenteral Amino Acid 15% No.536$8,292
DapagliflozinDapagliflozin Propanediol12$5,946
ProsolParenteral Amino Acid 20% No.138$5,518
ClinolipidFat Emulsion/Olive/Soy/Phospho11$3,893
Losartan Potassium199$1,841

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$172$214,24470 claims
AstraZenecaFarxiga, Lokelma$356$162,929208 claims
BayerKerendia$169$114,527136 claims
Akebia Therapeutics IncAuryxia$23$65,59634 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,070 nephrology providers in Texas.

Other nephrology in San Marcos

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →